Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Nuvalent Inc Cl A (NUVL)
Nuvalent Inc Cl A (NUVL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,168,854
  • Shares Outstanding, K 62,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -81,850 K
  • 60-Month Beta 1.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.45
Trade NUVL with:

Options Overview Details

View History
  • Implied Volatility 53.87% ( -1.82%)
  • Historical Volatility 36.03%
  • IV Percentile 10%
  • IV Rank 2.92%
  • IV High 171.33% on 09/15/23
  • IV Low 50.33% on 02/09/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 4
  • Volume Avg (30-Day) 421
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 14,739
  • Open Int (30-Day) 13,205

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.60
  • Number of Estimates 5
  • High Estimate -0.54
  • Low Estimate -0.68
  • Prior Year -0.49
  • Growth Rate Est. (year over year) -22.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.06 +13.67%
on 01/23/24
87.47 -3.76%
on 02/16/24
+4.83 (+6.09%)
since 01/22/24
3-Month
61.01 +37.97%
on 11/28/23
87.47 -3.76%
on 02/16/24
+21.68 (+34.70%)
since 11/22/23
52-Week
23.09 +264.52%
on 04/06/23
87.47 -3.76%
on 02/16/24
+52.58 (+166.41%)
since 02/22/23

Most Recent Stories

More News
Why Nuvalent Stock Tanked on Tuesday

The dilution monster stalked the company following the announcement of a new capital-raising effort.

PIPR : 185.85 (+0.37%)
NUVL : 84.76 (+2.70%)
Nuvalent Announces Pricing of Public Offering of Common Stock

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)
Nuvalent Announces Public Offering of Common Stock

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)
Why Nuvalent Stock Skyrocketed 35% This Week

Nuvalent announced favorable preliminary data in a clinical trial for its lung cancer drug. Here's what investors need to know.

NUVL : 84.76 (+2.70%)
Why Nuvalent Stock Was Soaring Wednesday

The company reported preliminary data on a non-small cell lung cancer therapy.

NUVL : 84.76 (+2.70%)
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)
Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)
Nuvalent to Participate in Upcoming September Investor Conferences

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

NUVL : 84.76 (+2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 85.88
2nd Resistance Point 84.25
1st Resistance Point 83.39
Last Price 84.76
1st Support Level 80.90
2nd Support Level 79.27
3rd Support Level 78.41

See More

52-Week High 87.47
Last Price 84.76
Fibonacci 61.8% 62.88
Fibonacci 50% 55.28
Fibonacci 38.2% 47.69
52-Week Low 23.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar